Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
DIENOGEST
Bayer Limited
G03DB08
DIENOGEST
2 Milligram
Tablets
Product subject to prescription which may be renewed (B)
Pregnadien derivatives
Authorised
2010-02-19
BP14138 1 PACKAGE LEAFLET: INFORMATION FOR THE USER VISANNE 2 MG TABLETS dienogest READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See Section 4. WHAT IS IN THIS LEAFLET: 1. What Visanne is and what it is used for 2. What you need to know before you take Visanne 3. How to take Visanne 4. Possible side effects 5. How to store Visanne 6. Contents of the pack and other information 1. WHAT VISANNE IS AND WHAT IT IS USED FOR Visanne is a preparation for the treatment of endometriosis (painful symptoms due to displaced tissue of the lining of the womb). Visanne contains a hormone, the progestogen dienogest. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE VISANNE DO NOT TAKE VISANNE IF YOU: are suffering from a BLOOD CLOT (thromboembolic disorder) in your veins. This may occur, for example, in the blood vessels of the legs (deep vein thrombosis) or the lungs (pulmonary embolism). See also _“Visanne and venous blood clots” _below_ _ have or have ever had a SEVERE ARTERIAL DISEASE, including cardiovascular disease, such as a HEART ATTACK, STROKE or HEART DISEASE which causes a reduced blood supply (angina pectoris). See also _"Visanne and arterial blood clots" _below have DIABETES with blood vessel damage have or have ever had SEVERE LIVER DISEASE (and your liver function values have n Preberite celoten dokument
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Visanne 2 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg dienogest Excipient with known effect: each tablet contains 62.8 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablets White to off-white, round, flat-faced, bevelled-edge tablets with a debossed “B” on one side and a diameter of 7 mm. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of endometriosis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Method of administration:_ For oral use. _Posology_ The dosage of Visanne is one tablet daily without any break, taken preferably at the same time each day with some liquid as needed. The tablet can be taken with or without food. Tablets must be taken continuously without regard to vaginal bleeding. When a pack is finished the next one should be started without interruption. There is no experience with Visanne treatment >15 months in patients with endometriosis. Treatment can be started on any day of the menstrual cycle. Any hormonal contraception needs to be stopped prior to initiation of Visanne. If contraception is required, non- hormonal methods of contraception should be used (e.g. barrier method). _Management of missed tablets:_ The efficacy of Visanne may be reduced in the event of missed tablets, vomiting and/or diarrhea (if occuring within 3-4 hours after tablet taking). In the event of one or more missed tablets, the woman should take one tablet only, as soon as she remembers, and should then continue the next day at her usual time. A tablet not absorbed due to vomiting or diarrhea should likewise be replaced by one tablet. _ADDITIONAL INFORMATION ON SPECIAL POPULATIONS_ HEALTH PRODUCTS REGULATORY AUTH Preberite celoten dokument